

TGA

THERAPEUTIC  
GOODS  
ADMINISTRATION

PO Box 100 Woden ACT 2606 Australia  
Telephone: (02) 6232 8444 Facsimile: (02) 6232 8241



Department of  
**Health and  
Aged Care**

## FACSIMILE

<b>Date:</b>	20 November 2001	<b>Total pages:</b>	1
<b>TO:</b>	GlaxoSmithKline Australia Ltd	<b>Telephone:</b>	[REDACTED]
<b>ATTENTION:</b>	[REDACTED]	<b>Facsimile:</b>	[REDACTED]
<b>Regarding:</b>	Request for further information – AU Army Safety Study trial		
<b>FROM:</b>	Rhonda Whybrow Clinical Trials Notification Officer	<b>Telephone:</b>	02 6232 8106
<b>Branch/Div.:</b>	Drug Safety & Evaluation Therapeutic Goods Administration	<b>Facsimile:</b>	02 6232 8112

---

If you do not receive all pages, please telephone the sender immediately

### MESSAGE

Dear [REDACTED]

I wish to acknowledge receipt of the Serious Adverse Event [REDACTED] which was received by the Therapeutic Goods Administration on 16 July 2001.

I have been asked to obtain additional information on the outcome or progress of this event.

Patient Initials: [REDACTED]  
DOB: [REDACTED]  
Country: East Timor

It would be appreciated if you could fax this information to me as soon as possible on (02) 6232 8112.

If you wish to discuss this matter further please contact me on (02) 6232 8106.

Regards

Rhonda Whybrow  
Clinical Trials Officer  
Experimental Drugs Section  
Drug Safety and Evaluation Branch